Astellas buys private UK gene therapy company specializing in treating glaucoma
Astellas Pharma Inc (OTC:APLMF) (SE:4503) announced on Friday it is buying privately held Quethera, a gene therapy company focused on developing treatments for eye disease, especially glaucoma.
Japan’s Astellas acquired UK-based Quethera’s program using a recombinant system which introduces therapeutic genes into target retinal cells to treat glaucoma, a disease that damages the eye’s optic nerve from a buildup of fluid in the front part of the organ. Glaucoma is the leading cause of blindness for people over 60 years old, according to the American Academy of Opthalmology.
Astellas president and chief executive Kenji Yasukawa said the deal “would address a high unmet medical need in glaucoma patients who are at risk of losing their eyesight.”
Shares of Astellas in Tokyo ended on Friday at 1,853 yen, off 0.4%, and having hit a session high of 1,862 yen, just short of the 52-week high of 1,869 yen.
In the US OTC market, Astellas shares finished on Thursday down 0.2% at US$16.62.
Under the terms of the agreement, Astellas may pay up to 85 million pounds (US$108.5mln) to Quethera shareholders in buying the company. Upon closing the transaction, Quethera becomes a wholly owned subsidiary of Astellas.
The impact of the transaction on Astellas’ financial results for the fiscal year ending on March 31, 2019, is “expected to be immaterial,” according to Astellas.
Astellas is based in Tokyo, Japan, which develops pharmaceutical products. Quethera is based in Cambridge, UK. It focuses on the treatment of diseases that blind people.
Contact Rene Pastor at [email protected]
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/202680/astellas-buys-private-uk-gene-therapy-company-specializing-in-treating-glaucoma-202680.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Lion’s Mane Mushroom
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, But it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes:
Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity.
Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins.
Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system.
Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome.
Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function.
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules. Today Be 100% Satisfied Or Receive A Full Money Back Guarantee Order Yours Today By Following This Link.
| Online: | |
| Visits: | 1,607,781,180 |
| Stories: | 8,162,874 |
Whistler Blowers, Insiders
